Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SN-001
- Development stage
- Preclinical
- Lead developer
- Kunming Sinoway Natural Pharmaceutical
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
SN-001 is a novel humanized immunotoxin being developed by Kunming SINOWAY Natural Pharmaceuticals in collaboration with Shanghai Jiaotong University. Classified as a Class 1 innovative biological drug in China, it consists of a humanized antibody or antibody fragment conjugated to a cytotoxic toxin. The drug is designed to selectively bind to target cells and deliver the toxin to induce cell death. As of current reports, SN-001 is in the preclinical development stage, specifically undergoing animal safety and toxicity testing. The specific biological target and therapeutic indications remain undisclosed by the developer.
Beyond the preview
Go deeper on SN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SN-001.